Ilomedin 20 Drug Interactions

In pharmacological experiments, iloprost has shown an additive effect on the antihypertensive activity of β-receptor blockers, calcium antagonists and vasodilators, and a potentiating effect on the antihypertensive activity of ACE inhibitors. These findings could not be confirmed in human volunteers. Should significant hypotension occur this can be corrected by reducing the dose of iloprost.
In animal experiments, the vasodilatory effect of iloprost is attenuated when the animals are pretreated with glucocorticoids, while the inhibitory effect on platelet aggregation remains unaffected. The significance of this finding for use in man is not yet known.
Because iloprost inhibits platelet function, its use with heparin or coumarin-type anticoagulants, which affect other hemostatic mechanisms, theoretically may increase the risk of bleeding. If this occurs, iloprost infusion should be stopped.
Iloprost has an additive or superadditive effect on platelet function with other inhibitors of platelet aggregation (acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs, phosphodiesterase inhibitors and nitrovasodilators (e.g. molsidomine).